Business Wire

CA-SOLIDIGM

6.8.2024 17:22:27 CEST | Business Wire | Press release

Share
Solidigm Extends AI SSD Portfolio Leadership with Lightning-Fast Additions to their D7 Product Line

Today, Solidigm, a leading provider of innovative NAND flash memory solutions, announced the launch of the SolidigmTM D7-PS1010 and D7-PS1030 data center solid-state drives (SSDs). As the fastest PCIe 5.0 SSDs1 shipping in volume today, these drives are well suited for the IO intensity found in modern mainstream, mixed, and write-centric workloads.

“The Solidigm D7-PS1010 and D7-PS1030 SSDs were meticulously engineered to meet the increasingly demanding IO requirements across a range of workloads such as general-purpose servers, OLTP, server-based storage, decision support systems and AI/ML,” said Greg Matson, Senior Vice President of Strategic Planning and Marketing at Solidigm. “In a world where every watt counts, these drives are PCIe 5.0 done right, not only delivering industry-leading four-corner performance,2 but also up to 70% better energy efficiency compared to similar drives by other manufacturers.3

Available in E3.S and U.2 form factors, the newest Solidigm SSDs come in a range of capacities and endurance options and are a strong extension to the company’s portfolio of best-in-industry storage for AI.

D7-PS1010

A standard endurance (SE) drive, the Solidigm D7-PS1010 is available in 1.92TB, 3.84TB, 7.68TB, and 15.36TB capacities. Over a 5-year period, the SE models provide 1.0 drive writes per day (DWPD) and boast substantial maximum lifetime program/erase cycles, with 28 petabytes written (PBW) for the 15.36TB variant. In server-based storage solutions, the D7-PS1010 can accelerate sequential write throughput up to 37 percent faster than drives with similar specifications.4 Offering a balance of performance and capacity, this drive is ideal for a wide range of mainstream applications.

D7-PS1030

A mid-endurance (ME) drive, the Solidigm D7-PS1030 is available in 1.6TB, 3.2TB, 6.4TB, and 12.8TB capacities and offers an impressive 70 PBW for the 12.8TB variant. When placed in an all-flash performance tier for AI workloads, the D7-PS1030 helps overcome hard disk drive (HDD) performance, endurance, and reliability limitations. With write performance more than double that of the previous generation Solidigm drive,5 the D7-PS1030 is particularly suited for operations requiring write-intensive usages such as caching and checkpointing.

The new drives are built to excel at every stage of the AI data pipeline and deliver up to 50 percent higher throughput in certain pipeline phases6 compared to similar drives in their class. These SSDs can be deployed as GPU direct attach drives in GPU servers or as part of a high-performance all-flash tier supporting lower-performing HDDs in network attach storage configurations.

“As AI workloads continue to surge, storage performance becomes critical,” said Ace Stryker, Director of Market Development at Solidigm. “The Solidigm D7-PS1010 and D7-PS1030 are a game-changer for AI-driven enterprises, capable of outperforming competitors at critical stages of the AI pipeline.”

With this launch, Solidigm continues its commitment to delivering industry-leading quality and reliability. By employing methodologies like testing to zero tolerance for data errors,7 built-in redundancies, enhanced power loss management, and engineering for performance consistency over the life of the drive,8 these SSDs far surpass required industry specifications and common practices. Combined with new OCP-compliant thermal management capabilities, and new security capabilities such as secure boot and data at rest protection and attestation, the D7-PS1010 and D7-PS1030 drives are designed to be deployed with utmost confidence in cloud and enterprise usages.

For more information on how Solidigm D7-PS1010 and Solidigm D7-PS1030 drives can help you power your workloads, visit our website.

About Solidigm

Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of team members in 13 locations around the world. For more information, please visit solidigm.com and follow us on Twitter and on LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).

______________________
1 Comparing product specifications and measured real-life workload performance across widely shipping PCIe 5.0 data center SSDs at the industry’s highest volume capacity point of 3.84TB (using Solidigm 2023 and 2024 shipments as industry representative data).

2 Four-corner comparison data is based on publicly available information from Samsung, Kioxia, and Micron.

3 Comparing 7.68TB, Samsung PM1743 and Solidigm D7-PS1010. Power is measured using Quarch Technology. Solidigm D7-PS1010 (128KB SW QD128 IOPS/Watt 3,874), Samsung PM1743 (128KB SW QD128 IOPS/Watt 2,272).

4 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. Comparing SolidigmTM D7-PS1010 3.84TB (128KB Seq Write QD128 8.2 MB/s) vs Samsung PM1743 3.84TB (128KB Seq Write QD128 6.0 MB/s).

5 As compared to previous generation Solidigm™ D7-P5520 and D7-P5620.

6 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. SolidigmTM D7-PS1010 7.68TB (32KB SW QD32 9.03GB/s 113us) vs Samsung PM1743 7.68TB (32K SW QD32 6.03GB/s 170us).

7 Solidigm drives are tested to 1E-18 under full range of conditions and cycle counts throughout the life of the drive which is 100X higher than 1E-16 specified in JEDEC – Solid State Drive Requirements and Endurance Test Method (JESD218). https://www.jedec.org/standards-documents/focus/flash/solid-state-drives.

8 Refer to SolidigmTM D7-PS1010 product specifications for IOPS consistency. Solidigm expects up to 5% variation in throughput between drive-to-drive runs. IOPS variability measured after adjusting SSD cycle limit to simulate end of life behavior. Results are estimated or simulated. Actual results may vary.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806563458/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye